Search
Indivior PLC
INDVAdd to Watchlist
41.290USD
-0.180-0.43%
Close 06/25, 16:00（ET）Quotes delayed by 15 min
5.00BMarket Cap
24.58P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.43%
5 Days
+7.81%
1 Month
+10.02%
6 Months
+14.19%
Year to Date
+15.08%
1 Year
+200.73%
Key Figures
41.500Open
42.070High
1.67MVolume
24.58P/E TTM
10.21P/E Dynamic
--Dividend TTM
1.37%Turnover Ratio
41.470Prev. Close
40.120Low
55.54MTurnover
2518.69P/E Static
-34.98P/B
0.00%Div Yield TTM
16.69%ROA
41.00052wk High
0.77Volume Ratio
2.00MNet Profit
122.00MShares
1.6800EPS TTM
1.18Beta
-307.32%ROE
12.04052wk Low
4.70%Amplitude
87.38%Gross Margin
5.00BMarket Cap
5.84Reward/Risk
2.01%Risk Rate
TradingKey Stock Score of Indivior PLC
Currency: USD Updated: 2026-06-25Key Insights
Indivior PLC's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 9 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 49.29.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Indivior PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Indivior PLC Highlights
StrengthsRisks
Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.
Fairly Valued
The company’s latest PE is 24.58, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 123.98M shares, decreasing 7.92% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 140.93K shares of this stock.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
49.286
Target Price
+23.34%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Indivior PLC News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Indivior PLC Info
Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.
Ticker SymbolINDV
CompanyIndivior PLC
CEOCiaffoni (Joseph J)
Websitehttps://www.indivior.com/en
Related Instruments
+1.16%
+1.66%
+3.67%
+1.27%
+4.05%
+1.48%
+0.40%
+0.44%
-1.05%
-1.48%
+1.05%
+0.75%
+1.55%
+1.14%
-0.20%
0.00%
-0.53%
+4.24%
+0.73%
-0.54%Popular Instruments
51852.400
-172.300 (-0.33%)
29071.200
-383.800 (-1.30%)
7313.800
-53.000 (-0.72%)
15201.000
-550.000 (-3.49%)
69279.000
-1853.000 (-2.60%)
6221.500
-44.300 (-0.71%)
70.378
-0.966 (-1.35%)
275.150
-17.930 (-6.12%)
195.740
-3.260 (-1.64%)
4018.130
-8.020 (-0.20%)
FAQs
What is the current price of Indivior PLC (INDV)?
The current price of Indivior PLC (INDV) is 41.29.
What is the symbol of Indivior PLC?
The ticker symbol of Indivior PLC is INDV.
What is the 52-week high of Indivior PLC?
The 52-week high of Indivior PLC is 41.00.
What is the 52-week low of Indivior PLC?
The 52-week low of Indivior PLC is 12.04.
What is the market capitalization of Indivior PLC?
The market capitalization of Indivior PLC is 5.04B.
Is Indivior PLC (INDV) currently rated as Buy, Hold, or Sell?
According to analysts, Indivior PLC (INDV) has an overall rating of Buy, with a price target of 49.29.
What is the Earnings Per Share (EPS TTM) of Indivior PLC (INDV)?
The Earnings Per Share (EPS TTM) of Indivior PLC (INDV) is 1.68.
